Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection.
BACKGROUND
M. bovis Bacille Calmette-Guérin (BCG), currently the only available vaccine against tuberculosis (TB), fails to adequately protect individuals from active and latent TB infection. New vaccines are desperately needed to decrease the worldwide burden of TB.


RESULTS
We created a recombinant strain of BCG that overproduces an L,D-transpeptidase in order to alter the bacterial peptidoglycan layer and consequently increase the ability of this immunogen to protect against virulent M. tuberculosis (Mtb). We demonstrate that this novel recombinant BCG protects mice against virulent Mtb at least as well as control BCG, as measured by its ability to reduce bacterial burden in lungs and spleen, reduce lung histopathology, and prolong survival. A nutrient starved recombinant BCG preparation, while offering comparable protection, elicited a response characterized by elevated levels of select Th1 cytokines.


CONCLUSIONS
Recombinant BCG overexpressing a L,D-transpeptidase that is nutrient starved elicits a stronger Th1 type response and is at least as protective as parent BCG. Results from this study suggest that nutrient starvation treatment of live BCG vaccines should be further investigated as a way to increase host induction of Th-1 related cytokines in the development of experimental anti-TB vaccines.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Scott T
ST
Nolan
Gyanu
G
Lamichhane
D000818:Animals; D001500:BCG Vaccine / Q000378:metabolism / Q000627:therapeutic use*; D001483:Base Sequence; D017931:DNA Primers; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000254:growth & development / Q000302:isolation & purification*; D010458:Peptidyl Transferases / Q000276:immunology / Q000378:metabolism*; D014376:Tuberculosis / Q000188:drug therapy*
D001500:BCG Vaccine; D017931:DNA Primers; D010458:Peptidyl Transferases